What is the price-to-earnings ratio of Opthea?
The price-earnings ratio of Opthea is currently -2.84.
Opthea P/E 2025
Opthea P/E
-2.84
Ticker
OPT.AX
ISIN
AU000000OPT2
WKN
A2AB8J
As of Sep 26, 2025, Opthea's P/E ratio was -2.84, a 94.52% change from the -1.46 P/E ratio recorded in the previous year.
The Opthea P/E history
Opthea Aktienanalyse
What does Opthea do?
Opthea Ltd is a biopharmaceutical company specializing in the development of novel therapies for various eye diseases. The company was founded in 1985 in Melbourne, Australia as a spin-off from the Burnet Institute for Medical Research and Public Health. Since then, Opthea has become a leading company in ophthalmology and is researching innovative therapies that have the potential to improve the lives of millions of patients worldwide. Opthea's business model is to develop novel therapies for various eye diseases and market these therapies through partnerships with established pharmaceutical companies. The company focuses on developing therapies based on the inhibition of growth factors and other signaling pathways that promote the development of abnormal blood vessels and inflammation. This therapeutic principle offers a promising way to effectively treat various eye diseases. Opthea specializes in developing therapies for the treatment of wet age-related macular degeneration (AMD), which is the leading cause of severe visual impairment in older people. Opthea is developing a therapy aimed at inhibiting the excessive formation of blood vessels in the macula of the eye, which can impair vision. The drug called OPT-302 is used in combination therapies with existing treatments for wet AMD and has the potential to slow down the progression of the disease and improve vision. In addition to the therapy for wet AMD, Opthea is also researching therapy options for other eye diseases such as diabetic retinopathy, retinal vein occlusion, and corneal diseases. Opthea has filed numerous patents in this field and collaborates with various academic and clinical partners to advance the development of innovative therapies. Another important component of Opthea's business model is collaboration with established pharmaceutical companies. In 2020, Opthea entered into a licensing agreement with the pharmaceutical company Novartis, which includes exclusive distribution and marketing rights for the drug OPT-302 in Europe, Japan, and other countries outside of North America. This partnership allows Opthea to benefit from collaboration with an experienced and established partner while maximizing the potential of its innovative therapy. In summary, Opthea is a promising company in ophthalmology that specializes in the development of innovative therapies for various eye diseases. The company works closely with academic and clinical partners and leverages the advantages of partnerships with established pharmaceutical companies to maximize the potential of its therapies. With the therapy for wet AMD already in the pipeline, Opthea is expected to develop further therapy options in the future that will contribute to improving the lives of millions of patients worldwide. Opthea ist eines der beliebtesten Unternehmen auf Eulerpool.com.P/E Details
Deciphering Opthea's P/E Ratio
The Price to Earnings (P/E) Ratio of Opthea is a vital metric that investors and analysts use to determine the company’s market value relative to its earnings. It is calculated by dividing the current stock price by the earnings per share (EPS). A higher P/E ratio could suggest that investors are expecting higher future growth, while a lower ratio may indicate a potentially undervalued company or lower growth expectations.
Year-to-Year Comparison
Assessing Opthea's P/E ratio on a yearly basis provides insights into the valuation trends and investor sentiment. An increasing P/E ratio over the years signifies growing investor confidence and expectations for future earnings growth, while a decreasing ratio may reflect concerns over the company's profitability or growth prospects.
Impact on Investments
The P/E ratio of Opthea is a key consideration for investors aiming to balance risk and reward. A comprehensive analysis of this ratio, in conjunction with other financial indicators, aids investors in making informed decisions regarding buying, holding, or selling the company’s stocks.
Interpreting P/E Ratio Fluctuations
Fluctuations in Opthea’s P/E ratio can be attributed to various factors including changes in earnings, stock price movements, and shifts in investor expectations. Understanding the underlying reasons for these fluctuations is essential for predicting future stock performance and assessing the company's intrinsic value.
Frequently Asked Questions about Opthea stock
How has the price-earnings ratio of Opthea changed compared to last year?
The price-to-earnings ratio of Opthea has increased by 94.52% increased compared to last year.
What consequences does a high price-earnings ratio have for investors?
A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.
What does a low price-earnings ratio mean?
A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.
Is the price-earnings ratio of Opthea high compared to other companies?
Yes, the price-to-earnings ratio of Opthea is high compared to other companies.
How does an increase in the price-earnings ratio of Opthea affect the company?
An increase in the price-earnings ratio of Opthea would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.
How does a reduction in the price-to-earnings ratio of Opthea affect the company?
A decrease in the price-earnings ratio of Opthea would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.
What are some factors that influence the price-earnings ratio of Opthea?
Some factors that influence the price-earnings ratio of Opthea are the company's growth, financial position, industry development, and the overall economic situation.
How much dividend does Opthea pay?
Over the past 12 months, Opthea paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Opthea is expected to pay a dividend of 0 USD.
What is the dividend yield of Opthea?
The current dividend yield of Opthea is .
When does Opthea pay dividends?
Opthea pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Opthea?
Opthea paid dividends every year for the past 0 years.
What is the dividend of Opthea?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Opthea located?
Opthea is assigned to the 'Health' sector.
Wann musste ich die Aktien von Opthea kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Opthea from 2/24/2005 amounting to 0.15 USD, you needed to have the stock in your portfolio before the ex-date on 2/4/2005.
When did Opthea pay the last dividend?
The last dividend was paid out on 2/24/2005.
What was the dividend of Opthea in the year 2024?
In the year 2024, Opthea distributed 0 USD as dividends.
In which currency does Opthea pay out the dividend?
The dividends of Opthea are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Opthea
Our stock analysis for Opthea Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Opthea Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
